Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology
ConclusionA weak recommendation is made that G-CSF treatment not be administered to patients with febrile neutropenia during cancer chemotherapy. G-CSF treatment can be considered for patients at high risk. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - May 2, 2024 Category: Cancer & Oncology Source Type: research
Upregulation of NPC1 and its association with poor prognosis in gastric cancer
ConclusionsNPC1 expression is upregulated in GC and serves as a pivotal prognostic factor for adverse outcomes in GC patients. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - May 2, 2024 Category: Cancer & Oncology Source Type: research
Relevance of Cardiovascular Exercise in Cancer and Cancer Therapy-Related Cardiac Dysfunction
AbstractPurpose of the ReviewCancer therapy-related cardiac dysfunction (CTRCD) has been identified as a threat to overall and cancer-related survival. Although aerobic exercise training (AET) has been shown to improve cardiorespiratory fitness (CRF), the relationship between specific exercise regimens and cancer survival, heart failure development, and reduction of CTRCD is unclear. In this review, we discuss the impact of AET on molecular pathways and the current literature of sports in the field of cardio-oncology.Recent FindingsCardio-oncological exercise trials have focused on variations of AET intensity by using mode...
Source: Current Heart Failure Reports - May 2, 2024 Category: Cardiology Source Type: research
Role of natural secondary metabolites as HIF-1 inhibitors in cancer therapy
AbstractHypoxia-inducible Factor 1 (HIF-1) is a transcriptional activator that intervenes in versatile reactions to hypoxia. Natural drugs, widely distributed in plants, comprise many metabolites, possessing their potential as anti-cancer agents. Studies have highlighted HIF-1 as a potential pharmacological target for cancer therapy. Secondary metabolites derived from natural products (plant-derived or marine organisms) with unique chemical structures have demonstrated HIF-1 inhibition. Ganetespib, topotecan, PX-478, aminoflavone, fluorine-19-fluoroded xyglucose, etc. have entered clinical phases of evaluation for differen...
Source: Medicinal Chemistry Research - May 2, 2024 Category: Chemistry Source Type: research
Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance
CONCLUSIONS: We identify a previously unappreciated cDC mechanism mediating Treg tumor infiltration after RT. Our findings suggest blocking the cDC1-CCL22-Treg axis augments RT efficacy. αEGFR-IFNα added to RT provided robust antitumor responses better than systemic free interferon administration, and may overcome clinical limitations to interferon therapy. Our findings highlight the complex behavior of cDC after RT and provide novel therapeutic strategies for overcoming RT-driven immunosuppression to improve RT efficacy.PMID:38691100 | DOI:10.1158/1078-0432.CCR-23-3616 (Source: Cell Research)
Source: Cell Research - May 1, 2024 Category: Cytology Authors: Jason Bugno Liangliang Wang Xianbin Yu Xuezhi Cao Jiaai Wang Xiaona Huang Kaiting Yang Andras Piffko Katherine Chen Stephen Y Luo Emile Naccasha Yuzhu Hou Sherry Fu Chuan He Yang-Xin Fu Hua Laura Liang Ralph R Weichselbaum Source Type: research
Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance
CONCLUSIONS: We identify a previously unappreciated cDC mechanism mediating Treg tumor infiltration after RT. Our findings suggest blocking the cDC1-CCL22-Treg axis augments RT efficacy. αEGFR-IFNα added to RT provided robust antitumor responses better than systemic free interferon administration, and may overcome clinical limitations to interferon therapy. Our findings highlight the complex behavior of cDC after RT and provide novel therapeutic strategies for overcoming RT-driven immunosuppression to improve RT efficacy.PMID:38691100 | DOI:10.1158/1078-0432.CCR-23-3616 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 1, 2024 Category: Cancer & Oncology Authors: Jason Bugno Liangliang Wang Xianbin Yu Xuezhi Cao Jiaai Wang Xiaona Huang Kaiting Yang Andras Piffko Katherine Chen Stephen Y Luo Emile Naccasha Yuzhu Hou Sherry Fu Chuan He Yang-Xin Fu Hua Laura Liang Ralph R Weichselbaum Source Type: research
Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy
Transl Oncol. 2024 Apr 30;45:101975. doi: 10.1016/j.tranon.2024.101975. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, mainly occurring in Asian countries with an increased incidence rate globally. Currently, several kinds of therapies have been deployed for HCC therapy including surgical resection, chemotherapy, radiotherapy and immunotherapy. However, this tumor is still incurable, requiring novel strategies for its treatment. The nanomedicine has provided the new insights regarding the treatment of cancer that liposomes as lipid-based nanoparticles, have been wid...
Source: Translational Oncology - May 1, 2024 Category: Cancer & Oncology Authors: Seyedeh Setareh Samaei Mahshid Daryab Sarah Gholami Aryan Rezaee Navid Fatehi Romina Roshannia Saeed Hashemi Nazanin Javani Parham Rahmanian Reza Amani-Beni Mohammad Arad Zandieh Noushin Nabavi Mohsen Rashidi Neda Malgard Mehrdad Hashemi Afshin Taheriazam Source Type: research
Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy
Transl Oncol. 2024 Apr 30;45:101975. doi: 10.1016/j.tranon.2024.101975. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, mainly occurring in Asian countries with an increased incidence rate globally. Currently, several kinds of therapies have been deployed for HCC therapy including surgical resection, chemotherapy, radiotherapy and immunotherapy. However, this tumor is still incurable, requiring novel strategies for its treatment. The nanomedicine has provided the new insights regarding the treatment of cancer that liposomes as lipid-based nanoparticles, have been wid...
Source: Cancer Control - May 1, 2024 Category: Cancer & Oncology Authors: Seyedeh Setareh Samaei Mahshid Daryab Sarah Gholami Aryan Rezaee Navid Fatehi Romina Roshannia Saeed Hashemi Nazanin Javani Parham Rahmanian Reza Amani-Beni Mohammad Arad Zandieh Noushin Nabavi Mohsen Rashidi Neda Malgard Mehrdad Hashemi Afshin Taheriazam Source Type: research
New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer
Biol Pharm Bull. 2024;47(5):895-903. doi: 10.1248/bpb.b23-00924.ABSTRACTEpidermal growth factor (EGF)-EGF receptor (EGFR) signaling studies paved the way for a basic understanding of growth factor and oncogene signaling pathways and the development of tyrosine kinase inhibitors (TKIs). Due to resistance mutations and the activation of alternative pathways when cancer cells escape TKIs, highly diverse cell populations form in recurrent tumors through mechanisms that have not yet been fully elucidated. In this review, we summarize recent advances in EGFR basic research on signaling networks and intracellular trafficking that...
Source: Biological and Pharmaceutical Bulletin - May 1, 2024 Category: Drugs & Pharmacology Authors: Yue Zhou Jun-Ichiro Takahashi Hiroaki Sakurai Source Type: research
Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance
CONCLUSIONS: We identify a previously unappreciated cDC mechanism mediating Treg tumor infiltration after RT. Our findings suggest blocking the cDC1-CCL22-Treg axis augments RT efficacy. αEGFR-IFNα added to RT provided robust antitumor responses better than systemic free interferon administration, and may overcome clinical limitations to interferon therapy. Our findings highlight the complex behavior of cDC after RT and provide novel therapeutic strategies for overcoming RT-driven immunosuppression to improve RT efficacy.PMID:38691100 | DOI:10.1158/1078-0432.CCR-23-3616 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 1, 2024 Category: Cancer & Oncology Authors: Jason Bugno Liangliang Wang Xianbin Yu Xuezhi Cao Jiaai Wang Xiaona Huang Kaiting Yang Andras Piffko Katherine Chen Stephen Y Luo Emile Naccasha Yuzhu Hou Sherry Fu Chuan He Yang-Xin Fu Hua Laura Liang Ralph R Weichselbaum Source Type: research
Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy
Transl Oncol. 2024 Apr 30;45:101975. doi: 10.1016/j.tranon.2024.101975. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, mainly occurring in Asian countries with an increased incidence rate globally. Currently, several kinds of therapies have been deployed for HCC therapy including surgical resection, chemotherapy, radiotherapy and immunotherapy. However, this tumor is still incurable, requiring novel strategies for its treatment. The nanomedicine has provided the new insights regarding the treatment of cancer that liposomes as lipid-based nanoparticles, have been wid...
Source: Translational Oncology - May 1, 2024 Category: Cancer & Oncology Authors: Seyedeh Setareh Samaei Mahshid Daryab Sarah Gholami Aryan Rezaee Navid Fatehi Romina Roshannia Saeed Hashemi Nazanin Javani Parham Rahmanian Reza Amani-Beni Mohammad Arad Zandieh Noushin Nabavi Mohsen Rashidi Neda Malgard Mehrdad Hashemi Afshin Taheriazam Source Type: research
New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer
Biol Pharm Bull. 2024;47(5):895-903. doi: 10.1248/bpb.b23-00924.ABSTRACTEpidermal growth factor (EGF)-EGF receptor (EGFR) signaling studies paved the way for a basic understanding of growth factor and oncogene signaling pathways and the development of tyrosine kinase inhibitors (TKIs). Due to resistance mutations and the activation of alternative pathways when cancer cells escape TKIs, highly diverse cell populations form in recurrent tumors through mechanisms that have not yet been fully elucidated. In this review, we summarize recent advances in EGFR basic research on signaling networks and intracellular trafficking that...
Source: Biological and Pharmaceutical Bulletin - May 1, 2024 Category: Drugs & Pharmacology Authors: Yue Zhou Jun-Ichiro Takahashi Hiroaki Sakurai Source Type: research
New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer
Biol Pharm Bull. 2024;47(5):895-903. doi: 10.1248/bpb.b23-00924.ABSTRACTEpidermal growth factor (EGF)-EGF receptor (EGFR) signaling studies paved the way for a basic understanding of growth factor and oncogene signaling pathways and the development of tyrosine kinase inhibitors (TKIs). Due to resistance mutations and the activation of alternative pathways when cancer cells escape TKIs, highly diverse cell populations form in recurrent tumors through mechanisms that have not yet been fully elucidated. In this review, we summarize recent advances in EGFR basic research on signaling networks and intracellular trafficking that...
Source: Biological and Pharmaceutical Bulletin - May 1, 2024 Category: Drugs & Pharmacology Authors: Yue Zhou Jun-Ichiro Takahashi Hiroaki Sakurai Source Type: research
New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer
Biol Pharm Bull. 2024;47(5):895-903. doi: 10.1248/bpb.b23-00924.ABSTRACTEpidermal growth factor (EGF)-EGF receptor (EGFR) signaling studies paved the way for a basic understanding of growth factor and oncogene signaling pathways and the development of tyrosine kinase inhibitors (TKIs). Due to resistance mutations and the activation of alternative pathways when cancer cells escape TKIs, highly diverse cell populations form in recurrent tumors through mechanisms that have not yet been fully elucidated. In this review, we summarize recent advances in EGFR basic research on signaling networks and intracellular trafficking that...
Source: Biological and Pharmaceutical Bulletin - May 1, 2024 Category: Drugs & Pharmacology Authors: Yue Zhou Jun-Ichiro Takahashi Hiroaki Sakurai Source Type: research
Stress-induced epinephrine promotes hepatocellular carcinoma progression via the USP10-PLAGL2 signaling loop
This study offers new understanding of stress’s role in cancer progression and potential targets for HCC treatment. The scientists concluded that more research is required to fully comprehend these results for future cancer therapies.This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author. (Source: Experimental and Molecular Medicine)
Source: Experimental and Molecular Medicine - May 1, 2024 Category: Molecular Biology Authors: Chen Wang Jiaping Ni Dongqing Zhai Yanchao Xu Zijie Wu Yuyuan Chen Ning Liu Juan Du Yumeng Shen Guilai Liu Yong Yang Linjun You Weiwei Hu Source Type: research
